Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) generates news as a clinical-stage biotechnology company focused on oncology medicines that target genetically determined dependencies within the chromatin regulatory system. Its updates frequently highlight progress from the Gene Traffic Control® platform, which systematically identifies and validates chromatin-based targets for small-molecule inhibitors and protein degraders.
News about FHTX often centers on its lead clinical candidate FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor being evaluated in a Phase 1 multi-center dose-escalation trial for SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population. Press releases describe preclinical data, trial enrollment status, and combination strategies with standard-of-care chemotherapies, pembrolizumab, and KRAS inhibitors in NSCLC models.
Investors following FHTX can also expect regular announcements on Foghorn’s selective degrader programs. These include a selective CBP degrader with potential in EP300-mutant cancers and ER+ breast cancer, a selective EP300 degrader for hematologic malignancies such as multiple myeloma and diffuse large B-cell lymphoma, and a selective ARID1B degrader for ARID1A-mutated solid tumors. Company communications summarize preclinical efficacy, tolerability, and formulation advances, as well as milestones such as progression into toxicology or IND-enabling studies.
Another recurring theme in Foghorn’s news flow is corporate and financial activity. Releases discuss collaboration revenue from its strategic partnership with Lilly, cash and marketable securities levels, and equity financings conducted under a shelf registration statement on Form S-3, including a registered direct financing that raised approximately $50 million in gross proceeds. Updates on leadership changes in the finance function and participation in healthcare and investor conferences also appear in FHTX news.
By monitoring this news page, readers can review company-issued information on trial progress, preclinical data, financing transactions, collaborations, and corporate developments that shape the ongoing story of Foghorn Therapeutics’ chromatin-focused oncology pipeline.
Etiome, unveiled by Flagship Pioneering with a $50 million initial commitment, introduces its Temporal Biodynamics™ AI-powered platform for preemptive healthcare. The platform represents the first end-to-end solution to detect and preempt disease progression before it becomes critical.
The technology characterizes disease progression over time by combining multimodal population-level data and single cell omics with artificial intelligence. It identifies Biostage Markers - stage-specific biomarkers indicating patient disease progression - and develops targeted Biostaged Medicines.
Initially focusing on metabolic, neurodegenerative, pre-cancerous, and autoimmune diseases, Etiome aims to reduce morbidity, lower healthcare costs, and extend healthy lifespans. The company emerges after four years of platform development under Flagship Pioneering's Preemptive Health and Medicine Initiative.
Foghorn Therapeutics (NASDAQ: FHTX) has announced a virtual investor event scheduled for April 29, 2025, at 8:00 a.m. ET to discuss key pipeline updates coinciding with the 2025 AACR Annual Meeting.
The company will present new preclinical combination data for FHD-909 (LY4050784), their potential first-in-class selective SMARCA2 inhibitor, targeting primarily non-small cell lung cancer (NSCLC). Additionally, Foghorn will share updates on their:
- Selective CBP degrader program's preclinical data in combination with chemotherapy and targeted agents
- Selective EP300 degrader program in hematological malignancies
- Selective ARID1B degrader program overview
The virtual event will review presentations from the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025. The webcast will be available on Foghorn's website with replay access post-event.
Flagship Pioneering has announced a new collaboration between its drug discovery unit Pioneering Medicines and Pfizer to discover potential novel inhibitors for autoimmune disease treatment. The partnership will utilize Logica, a platform developed by Valo Health and Charles River that combines AI-powered technology with drug discovery expertise to translate biological insights into optimized small molecules.
This marks the sixth agreement under the strategic partnership between Flagship Pioneering and Pfizer, following previous collaborations with ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines. The initiative aims to address the unmet needs in autoimmune disease management by developing more effective, safer, and personalized treatment options.
Foghorn Therapeutics (FHTX) announced new preclinical data presentations for its cancer treatment programs at the 2025 AACR Meeting. The company's lead candidate, FHD-909, a first-in-class selective SMARCA2 inhibitor, is currently advancing in Phase 1 trials for SMARCA4 mutated cancers, primarily targeting non-small cell lung cancer (NSCLC).
The presentations will showcase new preclinical combination data for FHD-909 with chemotherapy, pembrolizumab, and KRAS inhibitors. Additionally, the company will present data on their Selective CBP degrader and Selective EP300 degrader programs, which have demonstrated selective and robust anti-tumor activities.
The data will be presented through an oral presentation and multiple poster sessions at the AACR Annual Meeting in Chicago from April 25-30, 2025. The company reports that enrollment and dose escalation for the FHD-909 Phase 1 trial are progressing as planned.
Lila Sciences, founded by Flagship Pioneering in 2023, has emerged with a groundbreaking scientific superintelligence platform and autonomous labs for life, chemical, and materials sciences. The company has secured $200 million in seed financing from multiple investors including Flagship Pioneering, General Catalyst, and ARK Venture Fund.
The platform combines generative AI with autonomous AI science units to scale and optimize experimentation across scientific domains. Early achievements include developing advanced LLMs, generating optimal genetic medicine constructs, discovering novel antibodies, and creating cost-effective green hydrogen catalysts.
Led by CEO Geoffrey von Maltzahn and a team of experts including Chief Scientist George Church and CTO Andrew Beam, Lila's platform will be available to partners in life and material sciences industries to accelerate solutions in human health and sustainability.
Foghorn Therapeutics (FHTX) provided its financial update and 2024-2025 outlook, highlighting continued progress in its clinical programs. The company's lead candidate, FHD-909, a first-in-class oral selective SMARCA2 inhibitor, began Phase 1 trials for SMARCA4 mutated cancers in October 2024, focusing primarily on non-small cell lung cancer (NSCLC).
The company achieved selective degradation of ARID1B and is advancing its Selective CBP degrader and EP300 degrader programs. Preclinical combination data with pembrolizumab and KRAS inhibitors will be presented at AACR 2025.
Financial highlights show collaboration revenues of $22.6 million for 2024 (down from $34.2M in 2023), R&D expenses of $94.5 million (down from $109.7M), and a net loss of $86.6 million (improved from $98.4M). The company maintains a strong balance sheet with $243.7 million in cash and equivalents, providing runway into 2027.
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotechnology company focused on correcting abnormal gene expression, announced its participation in two upcoming investor conferences in February and March 2025.
The company will join the B. Riley Securities Precision Oncology and Radiopharma Conference on February 28, 2025, where President and CEO Adrian Gottschalk will participate in a Synthetic Lethality Panel at 9 a.m. EST in New York.
Additionally, Foghorn will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 2:30 p.m. EST in Boston, with management also conducting virtual one-on-one meetings that day.
Webcasts of the presentations will be available under the "Events & Presentations" section of Foghorn's website for 90 days. The company's Gene Traffic Control® platform focuses initially on oncology with potential applications across a wider spectrum of diseases.
YourBio Health and Flagship Pioneering have announced the appointment of Paul Owen as CEO of YourBio Health and CEO-Partner of Flagship Pioneering. Owen brings over 35 years of corporate leadership experience, most recently serving as Board Director and President of Oncodea.
YourBio Health's key product, the Touch-Activated Phlebotomy (TAP®) device, is the first push-button blood collection technology using microneedles for virtually painless blood draws. The technology has been implemented in clinical trials, diagnostic settings, and wellness applications, with millions of blood collections completed since its commercial launch.
The company has established partnerships with biopharmaceutical companies, genetic companies, and academic research hospitals. The announcement also includes concurrent appointments to YourBio's leadership team, adding expertise in medical device product innovation, clinical strategy, and commercialization.
Foghorn Therapeutics (NASDAQ: FHTX) has announced its strategic objectives for 2025, highlighting progress across multiple programs. The company's first-in-class oral selective SMARCA2 inhibitor, FHD-909, is advancing in Phase 1 trials for SMARCA4 mutated cancers, primarily targeting non-small cell lung cancer (NSCLC). Preclinical combination data with pembrolizumab and KRAS inhibitors will be presented at the AACR Annual Meeting in April 2025.
The company has achieved selective degradation of ARID1B, a synthetic lethal target implicated in up to 5% of all solid tumors, with an update expected in 2025. Foghorn is also advancing its Selective CBP degrader and Selective EP300 degrader programs. The company maintains a strong financial position with $243.8 million in cash, cash equivalents, and marketable securities, providing runway into 2027.
Foghorn Therapeutics (FHTX) announced the discontinuation of independent development for FHD-286 in combination with decitabine for relapsed/refractory acute myeloid leukemia (AML). While objective clinical responses were observed in the Phase 1 dose escalation trial, the response rate didn't meet the company's continuation threshold.
The company will now focus on its proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 inhibitor FHD-909. As of September 30, 2024, Foghorn reported $267.4 million in cash, cash equivalents, and marketable securities, providing runway into 2027. Trial results are expected to be presented at a medical conference in 2025.